GBIO

Generation Bio Co. is a biotechnology company. The Company is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. It focuses on autoimmune targets that have been undruggable or poorly drugged selectively in T cells. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.

Wall Street analysts forecast GBIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GBIO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Generation Bio Co revenue for the last quarter amounts to 1.59M USD, decreased -78.90 % YoY.

Generation Bio Co. EPS for the last quarter amounts to -0.82 USD, decreased -64.19 % YoY.

Generation Bio Co (GBIO) has 115 emplpoyees as of December 16 2025.

Today GBIO has the market capitalization of 36.32M USD.